317 related articles for article (PubMed ID: 36726053)
1. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives.
Huang SC; Liu CJ
Clin Mol Hepatol; 2023 Apr; 29(2):320-331. PubMed ID: 36726053
[TBL] [Abstract][Full Text] [Related]
2. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B.
Huang SC; Kao JH
J Formos Med Assoc; 2022 Nov; 121(11):2148-2151. PubMed ID: 35981929
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
Shang MY; Chen YZ; Bao J; Tong YL
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
[No Abstract] [Full Text] [Related]
5. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
[No Abstract] [Full Text] [Related]
6. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
7. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020.
van der Spek DPC; Katwaroe WK; van Kleef LA; Brakenhoff S; de Man RA; de Knegt RJ; van der Meer AJ; Sonneveld MJ
Eur J Intern Med; 2023 Jan; 107():86-92. PubMed ID: 36396524
[TBL] [Abstract][Full Text] [Related]
8. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors.
Yu MW; Lin CL; Liu CJ; Huang YW; Hu JT; Wu WJ; Wu CF
J Formos Med Assoc; 2022 Aug; 121(8):1478-1487. PubMed ID: 34764005
[TBL] [Abstract][Full Text] [Related]
9. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.
Chan AW; Wong GL; Chan HY; Tong JH; Yu YH; Choi PC; Chan HL; To KF; Wong VW
J Gastroenterol Hepatol; 2017 Mar; 32(3):667-676. PubMed ID: 27547913
[TBL] [Abstract][Full Text] [Related]
10. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
[TBL] [Abstract][Full Text] [Related]
11. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia.
Yang M; Wei L
Liver Int; 2022 Aug; 42(9):1981-1990. PubMed ID: 35373500
[TBL] [Abstract][Full Text] [Related]
12. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.
Shi YW; Yang RX; Fan JG
World J Gastroenterol; 2021 Jul; 27(26):3971-3983. PubMed ID: 34326608
[TBL] [Abstract][Full Text] [Related]
13. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
Wang X; Wei S; Wei Y; Wang X; Xiao F; Feng Y; Zhu Q
Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):889-898. PubMed ID: 37395242
[TBL] [Abstract][Full Text] [Related]
14. Systematic review: chronic viral hepatitis and metabolic derangement.
Wang CC; Cheng PN; Kao JH
Aliment Pharmacol Ther; 2020 Jan; 51(2):216-230. PubMed ID: 31746482
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
[TBL] [Abstract][Full Text] [Related]
16. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Li B; Cheung KS; Yuen MF; Seto WK
Hepatol Int; 2021 Aug; 15(4):901-911. PubMed ID: 34152534
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Hepatic Steatosis on the Natural History of HBV Infection.
Suliman I; Abdelgelil N; Kassamali F; Hassanein TI
Clin Liver Dis; 2019 Aug; 23(3):433-450. PubMed ID: 31266618
[TBL] [Abstract][Full Text] [Related]
18. Association between hepatitis B and metabolic syndrome: Current state of the art.
Jarcuska P; Drazilova S; Fedacko J; Pella D; Janicko M
World J Gastroenterol; 2016 Jan; 22(1):155-64. PubMed ID: 26755867
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
